Proactiveinvestors news media have interviewed Imagion Biosystems CEO Bob Proulx, who answers questions about the company’s early cancer detection technology, its place in the the medical imaging market, intellectual property protections, and more.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce